<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970096</url>
  </required_header>
  <id_info>
    <org_study_id>RG1005364</org_study_id>
    <secondary_id>9749</secondary_id>
    <secondary_id>NCI-2019-03188</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT03970096</nct_id>
  </id_info>
  <brief_title>Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia</brief_title>
  <official_title>A Phase II Randomized Controlled Trial Comparing Four GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia: Selective Depletion of CD45RA+ Na√Øve T Cells (TND) vs. CD34+-Selected Pan T Cell Depletion (CD34+) vs. Post-Transplantation Cyclophosphamide (PTCy) vs. Tacrolimus and Methotrexate (TacMTX) PBSCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial compares four strategies for the reduction of graft versus host disease
      in patients with acute leukemia in remission. Giving chemotherapy and total-body irradiation
      before a donor peripheral blood stem cell transplant helps stop the growth of cells in the
      bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also
      stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem
      cells from a donor are infused into the patient they may help the patient's bone marrow make
      stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may
      also replace the patient's immune cells and help destroy any remaining cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: Patients are randomized to 1 of 4 arms.

      ARM A: Patients undergo total-body irradiation (TBI) twice daily (BID) on days -10 to -7, and
      receive thiotepa intravenously (IV) over 4 hours on days -6 and -5, fludarabine IV over 30
      minutes on days -6 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV
      continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day
      0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute
      GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month
      for capsules (or per week for liquid).

      ARM B: Patients undergo TBI BID on days -9 to -6, and receive thiotepa IV over 4 hours on
      days -5 and -4, anti-thymocyte globulin IV over 6-8 hours on days -4 and -3, cyclophosphamide
      IV over 1 hour on days -3 and -2, and CD34+ enriched PBSC IV on day 0.

      ARM C: Patients undergo TBI BID on days -4 to -2 or -3 to -1, and receive PBSC IV on day 0.
      Patients also receive cyclophosphamide IV over 1 hour on days 3 and 4, and tacrolimus (or
      cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is
      no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or
      sirolimus) is tapered per month for capsules (or per week for liquid).

      ARM D: Patients undergo TBI BID on days -6 to -4, and receive cyclophosphamide IV over 1 hour
      on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV
      continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and
      11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or
      cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).

      After completion of study treatment, patients are followed up at days 7, 14, 21, 28, 56, 80,
      180, and 270 and at 1, 1.5, and 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft versus host disease (GVHD)-free relapse-free survival (RFS)</measure>
    <time_frame>At 2 years</time_frame>
    <description>Will be defined as survival-free of a history of: a) relapse after hematopoietic cell transplantation (HCT), b) grade III-IV acute GVHD after HCT, moderate or severe chronic GVHD meeting National Institutes of Health (NIH) criteria and requiring systemic pharmacologic immunosuppression for treatment of GVHD. RFS distribution will be estimated for each arm by the Kaplan-Meier curve, starting from the time of HCT. A 90% confidence interval (CI) will be constructed at 1 and 2-year post-HCT timepoints.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>At 2 years</time_frame>
    <description>Death will be considered as the event, and the OS distribution will be estimated for each group by the Kaplan-Meier method, starting from the time of HCT. A 90% CI will be constructed at the 1 and 2-year post-HCT time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>At 2 years</time_frame>
    <description>Will be defined as recurrence of leukemia (&gt;= 5% leukemic blasts by flow or morphology) in bone marrow, circulating leukemic blasts or extramedullary disease (extramedullary disease definite i.e. proven by biopsy or probably based on clinical assessment if biopsy not feasible). Lower levels of leukemia in bone marrow or blood will be recorded and reported as 'measurable residual disease' but will not be considered relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients alive and off prednisone (or equivalent systemic corticosteroid) for treatment of GVHD</measure>
    <time_frame>At 3, 6, 9, 12, 15, 18, 21, 24 months post HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft rejection or graft failure (&gt; 14 days duration)</measure>
    <time_frame>At 2 years</time_frame>
    <description>Will be operationally defined as failure to achieve an absolute neutrophil count (ANC) &gt;= 0.5 x 10^9/L before death or second HCT, or decrease to ANC &lt; 0.1 x 10^9/L for 14 consecutive days (date of graft failure defined as the 14th day) after an established donor graft despite daily administration of granulocyte colony-stimulating factor (subcutaneously or intravenously) and =&lt; 20% bone marrow cellularity on bone marrow aspirate or biopsy any time in the first 2 years following HCT. If the delay or reduction in ANC is due to relapse (as determined by histopathology, flow cytometry or cytogenetic or molecular studies) this will not be considered graft failure. If a patient dies from organ toxicity and/or infection prior to day 28 without ANC &gt;= 0.5 x 10^9/L this will not be considered graft failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be defined and graded based on NIH criteria and graded operationally as the occurrence of compatible symptoms.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Acute Biphenotypic Leukemia</condition>
  <condition>Acute Leukemia of Ambiguous Lineage</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Undifferentiated Leukemia</condition>
  <condition>Blastic Plasmacytoid Dendritic Cell Neoplasm</condition>
  <condition>Lymphoblastic Lymphoma</condition>
  <condition>Mixed Phenotype Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A (TnD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo TBI BID on days -10 to -7, and receive thiotepa IV over 4 hours on days -6 and -5, fludarabine IV over 30 minutes on days -6 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (CD34+ ATG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo TBI BID on days -9 to -6, and receive thiotepa IV over 4 hours on days -5 and -4, anti-thymocyte globulin IV over 6-8 hours on days -4 and -3, cyclophosphamide IV over 1 hour on days -3 and -2, and CD34+ enriched PBSC IV on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (PTCy, tacrolimus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo TBI BID on days -4 to -2 or -3 to -1, and receive PBSC IV on day 0. Patients also receive cyclophosphamide IV over 1 hour on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (tacrolimus, methotrexate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo TBI BID on days -6 to -4, and receive cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Arm A (TnD)</arm_group_label>
    <arm_group_label>Arm B (CD34+ ATG)</arm_group_label>
    <arm_group_label>Arm C (PTCy, tacrolimus)</arm_group_label>
    <arm_group_label>Arm D (tacrolimus, methotrexate)</arm_group_label>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
    <other_name>TBI</other_name>
    <other_name>Whole Body Irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (TnD)</arm_group_label>
    <arm_group_label>Arm B (CD34+ ATG)</arm_group_label>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thio-Tepa</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphamide</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Triethylene</other_name>
    <other_name>Triethylenethiophosphoramide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (TnD)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (TnD)</arm_group_label>
    <arm_group_label>Arm C (PTCy, tacrolimus)</arm_group_label>
    <arm_group_label>Arm D (tacrolimus, methotrexate)</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic CD34+-enriched and CD45RA-depleted PBSCs</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (TnD)</arm_group_label>
    <other_name>Allogeneic TN-depleted CD34-preserved PBSCs</other_name>
    <other_name>Allogeneic TND- CD34+ PBSCs</other_name>
    <other_name>Donor-derived TN Cell Depleted CD34-enriched PBSCs</other_name>
    <other_name>Naive T-cell Depleted CD34+ Allogeneic Peripheral Blood Stem Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (TnD)</arm_group_label>
    <arm_group_label>Arm D (tacrolimus, methotrexate)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B (CD34+ ATG)</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Antithymocyte Serum</other_name>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>ATS</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B (CD34+ ATG)</arm_group_label>
    <arm_group_label>Arm C (PTCy, tacrolimus)</arm_group_label>
    <arm_group_label>Arm D (tacrolimus, methotrexate)</arm_group_label>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Claphene</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cytophosphan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B (CD34+ ATG)</arm_group_label>
    <other_name>Allogeneic CD34+ PBSCs</other_name>
    <other_name>Allogeneic CD34+-enriched Peripheral Blood Stem Cells</other_name>
    <other_name>Donor-derived CD34-positive PBSCs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm C (PTCy, tacrolimus)</arm_group_label>
    <arm_group_label>Arm D (tacrolimus, methotrexate)</arm_group_label>
    <other_name>PBSC</other_name>
    <other_name>Peripheral Blood Stem Cells</other_name>
    <other_name>peripheral stem cell</other_name>
    <other_name>Peripheral Stem Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (TnD)</arm_group_label>
    <arm_group_label>Arm C (PTCy, tacrolimus)</arm_group_label>
    <arm_group_label>Arm D (tacrolimus, methotrexate)</arm_group_label>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Cyclosporine Modified</other_name>
    <other_name>Gengraf</other_name>
    <other_name>Neoral</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (TnD)</arm_group_label>
    <arm_group_label>Arm C (PTCy, tacrolimus)</arm_group_label>
    <arm_group_label>Arm D (tacrolimus, methotrexate)</arm_group_label>
    <other_name>RAPA</other_name>
    <other_name>Rapamune</other_name>
    <other_name>rapamycin</other_name>
    <other_name>SILA 9268A</other_name>
    <other_name>WY-090217</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are considered appropriate candidates for myeloablative, TBI-containing
             allogeneic hematopoietic stem cell transplantation and have one of the following
             diagnoses:

               -  Acute lymphocytic leukemia (ALL) in first or subsequent morphological remission
                  (&lt; 5% marrow blasts by morphology).

               -  Acute myeloid leukemia (AML) in first or subsequent morphological remission (&lt; 5%
                  marrow blasts by morphology).

               -  Other acute leukemia or related neoplasm (including but not limited to 'mixed
                  phenotype' 'biphenotypic', 'acute undifferentiated' or 'ambiguous lineage' acute
                  leukemia, blastic plasmacytoid dendritic cell neoplasm or lymphoblastic lymphoma)
                  in first or subsequent morphological remission (&lt; 5% marrow blasts by
                  morphology).

          -  Patient with an HLA-matched (HLA-A, B, C, DRB1, and DQB1 matched) related or unrelated
             donor capable of donating PBSC.

          -  Recipient informed consent/assent and/or legal guardian permission must be obtained.

          -  DONOR: HLA-matched related and unrelated donors (HLA-A, B, C, DRB1 and DQB1 matched
             based on high-resolution typing).

          -  DONOR: &gt;= 18 years old.

          -  DONOR: Willing to donate PBSC.

          -  DONOR: Matched related donors:

               -  Must give informed consent using the related donor informed consent form.

               -  Must meet institutional donor eligibility criteria or be ineligible with
                  statement that the donor is a first or second degree relative (exception 21 CRF
                  1271.65(b)(i)).

          -  DONOR: Matched unrelated donors:

               -  Must consent according to the applicable National Marrow Donor Program (NMDP)
                  donor regulatory requirements.

               -  Must meet eligibility criteria as defined by the NMDP or be ineligible with
                  statement of urgent medical need (exception 21 CRF 1271.65(b)(iii)).

        Exclusion Criteria:

          -  Patients with central nervous system (CNS) involvement refractory to intrathecal
             chemotherapy and/or standard cranial-spinal radiation. A patient may have a history of
             CNS disease. However, any CNS disease must be cleared by the end of the
             pre-conditioning evaluation time frame. If CNS disease is identified on cerebrospinal
             fluid (CSF) evaluation within 30 days of the start of the preparative regimen a repeat
             CSF evaluation must be performed and show no evidence of disease in order for the
             patient to be eligible for the protocol.

          -  Patients on other experimental protocols for prevention of GVHD.

          -  Patient weight:

               -  Patients with HLA-matched related donors will be excluded if they weigh &gt;= 100
                  kg.

               -  Patients with HLA-matched unrelated donors will be excluded if they weigh &gt;= 100
                  kg and must be discussed with the Fred Hutch protocol principal investigator (PI)
                  if they weigh &gt;= 80 kg.

          -  Patients who are positive for human immunodeficiency virus (HIV)-1, HIV-2, human
             T-cell lymphotropic virus (HTLV)1 or HTLV2.

          -  Patients with uncontrolled infections for whom myeloablative HCT is considered
             contraindicated by the consulting infectious disease physician; i.e. patients with
             active infections require infectious disease consultation and documentation by the
             infectious disease team that myeloablative HCT is not considered to be
             contraindicated. Upper respiratory tract infection is not considered to represent an
             uncontrolled infection in this context.

          -  Patients with organ dysfunction, including:

               -  Renal insufficiency (creatinine &gt; 1.5 mg/dl) at the time of evaluation for the
                  protocol. Patients with a known history of creatinine &gt; 1.5 mg/dl or a current
                  serum creatinine above the normal range for age must have a current creatinine
                  clearance of &gt; 60 ml/min/1.73 m^2 (measured by 24-hr urine specimen or nuclear
                  glomerular filtration rate [GFR]).

               -  Left ventricular ejection fraction &lt; 45%.

               -  Carbon monoxide diffusing capability (DLCO) corrected &lt; 60%. Patients who are
                  unable to perform pulmonary function tests (for example, due to young age and/or
                  developmental status) will be excluded if the oxygen (O2) saturation is &lt; 92% on
                  room air.

               -  Liver function abnormality. Patients who have liver function test (LFT)s
                  (specifically, total bilirubin, aspartate aminotransferase [AST] or alanine
                  aminotransferase [ALT]) &gt;= twice the upper limit of normal should be evaluated by
                  a gastrointestinal (GI) physician unless there is a clear precipitating factor
                  (such as an azole, MTX, trimethoprim-sulfamethoxazole, or another drug). If the
                  GI physician considers that HCT on the protocol is contraindicated, that patient
                  will be excluded from the protocol. Patients with Gilbert's syndrome and no other
                  known liver function abnormality or with reversible drug-related transaminitis do
                  not necessarily require GI consultation and may be included on the protocol.

          -  Patients who have received previous myeloablative allogeneic or autologous
             transplantation.

          -  Patients with a life expectancy &lt; 12 months from co-existing disease other than the
             leukemia.

          -  Patients who are pregnant or breast-feeding.

          -  Patients of childbearing age who are presumed to be fertile and are unwilling to use
             an effective birth control method or refrain from sexual intercourse during and for 12
             months post-HCT.

          -  Patients with any other significant medical conditions that would make them unsuitable
             for transplantation, as determined by the PI.

          -  Patients with a known hypersensitivity to tacrolimus or MTX.

          -  DONOR: Donors who are HIV-1, HIV-2, HTLV-1, HTLV-2 seropositive or with active
             hepatitis B or hepatitis C virus infection. Test must be performed using Food and Drug
             Administration (FDA) licensed, cleared, and approved test kits (serological and/or
             nucleic acid amplification test [NAT] and/or other approved testing) in a Clinical
             Laboratory Improvement Act (CLIA)-certified laboratory.

          -  DONOR: Unrelated donors donating outside of the United States of America (USA).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Bleakley</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Bleakley</last_name>
    <phone>206-667-6572</phone>
    <email>mbleakle@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taiga Nishihori</last_name>
      <phone>813-745-4673</phone>
      <email>taiga.nishihori@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Taiga Nishihori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alison Sehgal</last_name>
      <phone>412-623-2861</phone>
      <email>sehgalar@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Alison Sehgal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Bleakley</last_name>
      <phone>206-667-6572</phone>
      <email>mbleakle@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Marie Bleakley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

